Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Yizhi Cao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5995-6347; OpenAlex author ID A5102908865. Sources: OpenAlex.

Their work

Papers
17 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
59
Papers, trials and grants by year

2022: 4 papers · 2023: 4 papers · 2024: 2 papers · 2025: 6 papers · 2026: 1 paper

Papers 17

  1. LINC01137 facilitates pancreatic cancer stemness, chemoresistance and proliferation via the miR-7155-5p/KLF12/PI3K-Akt axis. Co-author DOI 10.1016/j.ijbiomac.2026.150088↗
  2. H19 promotes polarization and alternative splicing in tumor-associated macrophages, facilitating pancreatic cancer progression. Co-author DOI 10.1016/j.canlet.2024.217389↗
  3. CEMIP2 sensitizes PDAC to chemotherapy through extracellular matrix remodeling by hyaluronan degradation. Co-author DOI 10.1016/j.canlet.2025.217898↗
  4. TFAP2A enhances tumor stemness and promotes metastasis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.isci.2025.113060↗
  5. The power and the promise of CAR-mediated cell immunotherapy for clinical application in pancreatic cancer. First author DOI 10.1016/j.jare.2024.01.014↗
  6. CTCF enhances pancreatic cancer progression via FLG-AS1-dependent epigenetic regulation and macrophage polarization. Co-author DOI 10.1038/s41418-024-01423-1↗
  7. Identification of a Novel Small Molecule STING Agonist Reshaping the Immunomicroenvironment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.7150/ijbs.107837↗
  8. BHLHE40 Inhibits Ferroptosis in Pancreatic Cancer Cells via Upregulating SREBF1. Co-author DOI 10.1002/advs.202306298↗
  9. ATF3-induced activation of NF-κB pathway results in acquired PARP inhibitor resistance in pancreatic adenocarcinoma. First author DOI 10.1007/s13402-023-00907-5↗
  10. A microprotein N1DARP encoded by LINC00261 promotes Notch1 intracellular domain (N1ICD) degradation via disrupting USP10-N1ICD interaction to inhibit chemoresi… Co-author DOI 10.1038/s41421-023-00592-6↗
  11. Schwann cells regulate tumor cells and cancer-associated fibroblasts in the pancreatic ductal adenocarcinoma microenvironment. Co-author DOI 10.1038/s41467-023-40314-w↗
  12. LINC01137 facilitates pancreatic cancer stemness via the miR-7155-5p/KLF12/AKT axis Co-author DOI 10.21203/rs.3.rs-2411868/v1↗
  13. Comprehensive machine learning-generated classifier identifies pro-metastatic characteristics and predicts individual treatment in pancreatic cancer: A multice… First author DOI 10.7150/thno.84978↗
  14. The CTCF/LncRNA-PACERR complex recruits E1A binding protein p300 to induce pro-tumour macrophages in pancreatic ductal adenocarcinoma via directly regulating P… Co-author DOI 10.1002/ctm2.654↗
  15. LncRNA-PACERR induces pro-tumour macrophages via interacting with miR-671-3p and m6A-reader IGF2BP2 in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13045-022-01272-w↗
  16. LINC01137 involvement in pancreatic cancer stemness via the miR-7155-5p/KLF12/AKT axis Co-author DOI 10.21203/rs.3.rs-1516835/v1↗
  17. LINC01137 facilitate pancreatic cancer stemness via the miR-7155-5p/KLF12/AKT axis Co-author DOI 10.21203/rs.3.rs-2065916/v1↗

Closest collaborators

The 25 strongest of 59 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Baiyong Shen · 10 shared papers, 2022–2025 · strength 1.69
  2. Lingxi Jiang · 8 shared papers, 2022–2025 · strength 1.37
  3. Shuyu Zhai · 7 shared papers, 2023–2025 · strength 1.25
  4. Chenghong Peng · 8 shared papers, 2022–2025 · strength 1.19
  5. Pengyi Liu · 6 shared papers, 2022–2025 · strength 1.03
  6. Xiaomei Tang · 5 shared papers, 2023–2025 · strength 0.91
  7. Kai Qin · 5 shared papers, 2022–2026 · strength 0.83
  8. Chenlei Wen · 5 shared papers, 2022–2025 · strength 0.83
  9. Jiayu Lin · 4 shared papers, 2024–2025 · strength 0.80
  10. Yang Liu · 4 shared papers, 2024–2025 · strength 0.77
  11. Jiewei Lin · 5 shared papers, 2022–2025 · strength 0.73
  12. Lijie Han · 5 shared papers, 2022–2024 · strength 0.69
  13. Xiaxing Deng · 4 shared papers, 2022–2026 · strength 0.68
  14. Yihao Liu · 4 shared papers, 2022–2025 · strength 0.65
  15. Zengyu Feng · 4 shared papers, 2022–2026 · strength 0.65
  16. Jiaxin Luo · 4 shared papers, 2022–2025 · strength 0.64
  17. Youwei Zhu · 4 shared papers, 2022–2024 · strength 0.61
  18. Dongjie Chen · 3 shared papers, 2023–2025 · strength 0.57
  19. Yongsheng Jiang · 4 shared papers, 2022–2024 · strength 0.56
  20. Meilin Xue · 3 shared papers, 2023–2025 · strength 0.50
  21. Weishen Wang · 3 shared papers, 2023–2024 · strength 0.49
  22. Xiaxing Deng · 3 shared papers, 2023–2024 · strength 0.47
  23. Kexian Li · 2 shared papers, 2025–2026 · strength 0.46
  24. Hao Chen · 3 shared papers, 2023–2024 · strength 0.44
  25. Jiancheng Wang · 3 shared papers, 2022–2023 · strength 0.42

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.